Evidence map›Paper›PMID 35994504›Full record

ArticleThe Journal of infectious diseases2022

The Influence of Sex, Body Mass Index, and Age on Cellular and Humoral Immune Responses Against Measles After a Third Dose of Measles-Mumps-Rubella Vaccine.

Huy Quang Quach, Jun Chen, Jonathon M Monroe, Tamar Ratishvili, Nathaniel D Warner, Diane E Grill, Iana H Haralambieva, Inna G Ovsyannikova, Gregory A Poland, Richard B Kennedy

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Huy Quang QuachMayo Clinic Vaccine Research Group, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Jun ChenDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-1273-5624
Jonathon M MonroeMayo Clinic Vaccine Research Group, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Tamar RatishviliMayo Clinic Vaccine Research Group, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Nathaniel D WarnerDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Diane E GrillDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Iana H HaralambievaMayo Clinic Vaccine Research Group, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Inna G OvsyannikovaMayo Clinic Vaccine Research Group, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Gregory A PolandMayo Clinic Vaccine Research Group, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Richard B KennedyMayo Clinic Vaccine Research Group, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic in Florida · US

Funding

Understanding measles vaccine failure (and success) in Southern IndiaR01AI121054 · NIAID · MAYO CLINIC ROCHESTER · PI JACOB, JOSHY, KENNEDY, RICHARD B · 2017 to 2021
$3.8M
Genetic Markers of Long-Term Mumps Vaccine ImmunityR01AI127365 · NIAID · MAYO CLINIC ROCHESTER · PI KENNEDY, RICHARD B · 2016 to 2020
$3.6M
NIAID NIH HHS R01 AI121054NIAID NIH HHS R01 AI127365
6 · The paper itself

Abstract

backgroundA third dose of measles-mumps-rubella vaccine (MMR3) is recommended in mumps outbreak scenarios, but the immune response and the need for widespread use of MMR3 remain uncertain. Herein, we characterized measles-specific immune responses to MMR3 in a cohort of 232 healthy subjects.

methodsSerum and peripheral blood mononuclear cells (PBMCs) were sampled at day 0 and day 28 after MMR3. Measles-specific binding and neutralizing antibodies were quantified in sera by enzyme-linked immunosorbent assay and a microneutralization assay, respectively. PBMCs were stimulated with inactivated measles virus, and the release of cytokines/chemokines was assessed by a multiplex assay. Demographic variables of subjects were examined for potential correlations with immune outcomes.

resultsOf the study participants, 95.69% and 100% were seropositive at day 0 and day 28, respectively. Antibody avidity significantly increased from 38.08% at day 0 to 42.8% at day 28 (P = .00026). Neutralizing antibodies were significantly enhanced, from 928.7 at day 0 to 1289.64 mIU/mL at day 28 (P = .0001). Meanwhile, cytokine/chemokine responses remained largely unchanged. Body mass index was significantly correlated with the levels of inflammatory cytokines/chemokines.

conclusionsMeasles-specific humoral immune responses, but not cellular responses, were enhanced after MMR3 receipt, extending current understanding of immune responses to MMR3 and supporting MMR3 administration to seronegative or high-risk individuals.

Indexed as

MeaslesMumpsRubellaAntibodies, NeutralizingAntibodies, ViralBody Mass IndexChemokinesCytokinesHumansImmunity, HumoralLeukocytes, MononuclearMeasles-Mumps-Rubella VaccineMeasles VaccineAntibodies, NeutralizingAntibodies, ViralChemokinesCytokinesMeasles-Mumps-Rubella VaccineMeasles Vaccinecellular immunityhumoral immunitymeasles virusMMR3MMR vaccine

Identifiers

PMID35994504
PMCPMC10205623
OpenAlexW4292636440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.